Search Results for "Pregnancy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Pregnancy. Results 81 to 90 of 968 total matches.
In Brief: Plan B OTC
The Medical Letter on Drugs and Therapeutics • Sep 11, 2006 (Issue 1243)
the pregnancy
rate to 1%, compared to an expected rate of 8% (Task
Force on Postovulatory Methods of Fertility ...
The FDA has approved over-the-counter (OTC) sales of Plan B (Duramed), an emergency contraceptive package that contains two 0.75-mg tablets of levonorgestrel, to women ≥18 years old. Younger women still require a prescription. In one trial, two levonorgestrel 0.75-mg tablets taken 12 hours apart, the first within 72 hours after unprotected intercourse, decreased the pregnancy rate to 1%, compared to an expected rate of 8% (Task Force on Postovulatory Methods of Fertility Regulation, Lancet 1998; 352:428). How high doses of a progestin taken after coitus prevent pregnancy is unclear; they may...
Symfi, Symfi Lo, and Cimduo for HIV (online only)
The Medical Letter on Drugs and Therapeutics • Jan 14, 2019 (Issue 1563)
advantages over TDF in the absence of
pharmacokinetic enhancement is unclear.9
PREGNANCY — Although use ...
The FDA has approved three new once-daily fixed-dose
antiretroviral drug combinations for treatment of HIV-1 infection. Symfi and Symfi Lo (Mylan) contain the
non-nucleoside reverse transcriptase inhibitor (NNRTI)
efavirenz and the nucleoside reverse transcriptase
inhibitors (NRTIs) lamivudine and tenofovir disoproxil
fumarate (TDF) and were approved as complete
antiretroviral regimens. Symfi Lo contains a lower
dose of efavirenz than both Symfi and Atripla, a fixed-dose
combination of efavirenz, TDF, and the NRTI
emtricitabine that was approved in 2006. Cimduo
(Mylan), which...
In Brief: Femlyv – An Orally Disintegrating Hormonal Contraceptive
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024 (Issue 1717)
and norethindrone
acetate, has been approved by the FDA for prevention
of pregnancy in females with a body mass ...
Femlyv (Millicent), an orally disintegrating tablet
containing ethinyl estradiol and norethindrone
acetate, has been approved by the FDA for prevention
of pregnancy in females with a body mass index (BMI)
≤35 kg/m2. It is the first hormonal contraceptive to
become available in an orally disintegrating tablet
formulation. Traditional oral and chewable tablets
containing ethinyl estradiol and norethindrone acetate
in a wide range of doses, including those found in
Femlyv, have been available in the US for years.
Med Lett Drugs Ther. 2024 Dec 9;66(1717):200 doi:10.58347/tml.2024.1717c | Show Introduction Hide Introduction
Drugs for Hypertensive Emergencies
The Medical Letter on Drugs and Therapeutics • Apr 07, 1989 (Issue 789)
vascular surgery; hypertensive crisis due to pheochromocytoma or occurring during pregnancy ...
Hypertensive emergencies include hypertensive encephalopathy, intracranial hemorrhage with hypertension, aortic dissection, acute pulmonary edema with hypertension, acute cardiac ischemia with hypertension, malignant hypertension and severe hypertension after vascular surgery; hypertensive crisis due to pheochromocytoma or occurring during pregnancy is not discussed in this review. Although immediate reduction of blood pressure is necessary in hypertensive emergencies, an excessive decrease may cause stroke, myocardial infarction or visual changes. Most experienced clinicians aim...
Zuranolone (Zurzuvae) – An Oral Drug for Postpartum Depression
The Medical Letter on Drugs and Therapeutics • Dec 25, 2023 (Issue 1692)
.
the major metabolite of progesterone. Allopregnanolone
levels rise during pregnancy, peak in the third ...
The FDA has approved the oral GABAA receptor
modulator zuranolone (Zurzuvae – Sage Therapeutics/Biogen) for treatment of postpartum depression
(PPD). Zuranolone is the second drug to be approved
for this indication; brexanolone (Zulresso), another
GABAA receptor modulator, was approved for IV
treatment of PPD in 2019.
Med Lett Drugs Ther. 2023 Dec 25;65(1692):201-3 doi:10.58347/tml.2023.1692a | Show Introduction Hide Introduction
Table: Treatments Considered for COVID-19 (Archived) (online only)
The Medical Letter on Drugs and Therapeutics • Apr 06, 2020 (Issue 1595)
for administration via enteral tube
Use in Pregnancy:
Does not appear to increase the risk of major birth ...
View the Table: Treatments Considered for COVID-19
Drugs for Psoriatic Arthritis
The Medical Letter on Drugs and Therapeutics • Dec 30, 2019 (Issue 1588)
(Soriatane, and
generics), may increase the risk of hepatotoxicity.
Pregnancy and Lactation – Methotrexate ...
Psoriatic arthritis is a chronic inflammatory
arthropathy associated with psoriasis. A recent review
found that about 20% of patients with psoriasis have
psoriatic arthritis. Updated guidelines for treatment
of psoriatic arthritis have recently been published.
Lipid-Lowering Drugs
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022 (Issue 1659)
to interfere with the absorption of most statins.
Pregnancy and Lactation – Statins are no longer ...
Cholesterol management guidelines from the
American College of Cardiology/American Heart
Association Task Force were last published in 2019.
Treatment of Allergic Rhinitis and Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • Mar 31, 2025 (Issue 1725)
of intranasal drugs.1
PREGNANCY — In a systematic review and metaanalysis
of 37 studies that included >50,000 ...
Initial treatment of allergic rhinitis (AR) depends
on the severity of symptoms and whether they are
intermittent or persistent (see Table 1).
Med Lett Drugs Ther. 2025 Mar 31;67(1725):49-56 doi:10.58347/tml.2025.1725a | Show Introduction Hide Introduction
Seasonale
The Medical Letter on Drugs and Therapeutics • Feb 02, 2004 (Issue 1175)
in the US
for pregnancy prevention. Active tablets containing 30 µg of ethinyl estradiol and 0.15 mg of levonorgestrel ...
Seasonale (Barr), the first "extended-cycle" oral contraceptive, is now available in the US for pregnancy prevention. Active tablets containing 30 ╡g of ethinyl estradiol and 0.15 mg of levonorgestrel are taken for 84 consecutive days, followed by 7 days of inactive tablets, allowing for withdrawal bleeding only four times a year. Other combination oral contraceptives are dispensed as 21 days of active tablets and 7 days of placebo or no tablets, resulting in 13 withdrawal bleeding episodes each year.